Waters Launches Xevo CDMS – A Game-Changer for Mega-Mass Biomolecule Analysis

Waters

Waters Corporation has introduced the Waters Xevo Charge Detection Mass Spectrometer (CDMS), a cutting-edge tool designed to address the increasing complexity of biotherapeutic molecules in modern drug development. As labs pivot to cell and gene therapies, mRNA, and large protein therapeutics, the demand for precise and scalable measurement solutions grows.

The Xevo CDMS is a first-of-its-kind system enabling direct, individual-particle mass measurements for biomolecules up to 150+ MDa. This powerful capability allows users to analyze protein complexes, nucleic acids, lipid nanoparticles, and viral vectors with unprecedented accuracy and efficiency.

Top Features of the Xevo CDMS:

  • Measures large, heterogeneous molecules without the need for deconvolution or digestion.

  • Operates with up to 100x less sample volume than traditional techniques.

  • Delivers results in under 10 minutes at low concentrations (as low as 10^10 vp/mL).

  • Powered by GxP-ready waters_connect™ Software.

"Waters continues to make strategic investments in large molecules, recognizing that advanced tools for bioanalytical characterization play a critical role in driving therapeutic breakthroughs," said Udit Batra, Ph.D., President and CEO, Waters Corporation. "We believe the Xevo CDMS will accelerate the global development of genetic medicines and other advanced modalities."

Transforming Equipment Portfolios

For laboratories investing in the future of therapeutic development, the Xevo CDMS is more than just an analytical tool—it is an essential platform to enhance workflow efficiency, reduce sample waste, and unlock new scientific insights.

The core innovation, the Electrostatic Linear Ion Trap (ELIT), was developed by Indiana University and Megadalton Solutions. Waters acquired these assets in 2022, ensuring the commercialization of this transformative technology.

Now available to order, the Xevo CDMS positions labs at the forefront of next-gen biotherapeutics.